Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

• Status: Active, not recruiting
• Trial end date: 2025-12-01

Summary

Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and in lenalidomide maintenance treatment

• Phase: Phase 3

Details

• Lead Sponsor: University of Heidelberg Medical Center
• Treatments: BB 1101; Bortezomib; Dexamethasone; Dexamethasone acetate; Lenalidomide; Thalidomide